Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Pituitary pars intermedia dysfunction (PPID) is probably the most common disease of geriatric horses. Affected horses show a variety of clinical signs, including hirsutism, polyuria/polydipsia, immunosuppression, muscle wasting, and laminitis. The most common treatment for PPID is pergolide, a dopamine agonist; however, there are no pharmacokinetic data about the use of this drug in horses. This article describes a study designed to address this complete lack of pharmacokinetic information. The pharmacokinetics of pergolide are described in a small group of relatively young, healthy mares (n = 6), with the objective of generating data on which to base larger studies in the future. To make definitive dosing recommendations to clinicians, more studies will be needed to investigate the relationship between plasma pergolide concentrations and clinical outcomes, as well as the effect of gender, age, and concomitant disease on the absorption and disposition of this drug.
Gehring
Ronette
R
Department of Clinical Sciences (Agricultural Practices), College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
Beard
Laurie
L
Wright
Abra
A
Coetzee
Johann
J
Havel
James
J
Apley
Michael
M
D000284:Administration, Oral; D000818:Animals; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006736:Horses / Q000097:blood / Q000378:metabolism*; D010479:Pergolide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D018491:Dopamine Agonists; D010479:Pergolide